ubmslateRN-logo-ubm

RN Mobile Menu

Search form

Topics:

Hydroxychloroquine for RA Boosts Metabolic, Cardiovascular Profile: Page 2 of 2

Hydroxychloroquine for RA Boosts Metabolic, Cardiovascular Profile: Page 2 of 2

• Hemoglobin A1c was reduced in patients with rheumatoid arthritis who were taking hydroxychloroquine (−0.19±0.13%).

• Overall cardiovascular risk was reduced in patients with rheumatoid arthritis taking hydroxychloroquine (retrospective study odds ratio [OR], 0.27 [95% CI, 0.16 to 0.46]; case-control study adjusted OR, 0.45 [95% CI, 0.10 to 2.0]).

• In a recent retrospective study, hydroxychloroquine was associated with a reduced risk of cardiovascular disease (adjusted hazard ratio [HR], 0.60 [95% CI, 0.41 to 0.94], p=0.02) as well as a reduced incidence of composite coronary artery disease, stroke, and transient ischemic attack (adjusted HR, 0.67 [95% CI, 0.42 to 1.070], p=0.09).

Implications for physicians

• Because of a positive effect on both metabolic parameters and cardiovascular risk in patients with rheumatoid arthritis, hydroxychloroquine should be considered in combination therapy, especially in patients at higher risk for diabetes and cardiovascular disease.

• Patients who have rheumatoid arthritis with hyperglycemia, hyperlipidemia, or baseline cardiovascular risk factors may benefit from hydroxychloroquine treatment irrespective of the treatment for rheumatoid arthritis.

• Hydroxychloroquine is well tolerated and as such is a safe and well-established adjunct to other disease-modifying antirheumatic drugs in the treatment of patients with rheumatoid arthritis.

Pages

References

Rempenault C, Combe B, Barnetche T, et al. “Metabolic and cardiovascular benefits of hydroxychloroquine in patients with rheumatoid arthritis: a systematic review and meta-analysis.” Ann Rheum Dis. 2017 Sep 25. pii: annrheumdis-2017-211836. doi: 10.1136/annrheumdis-2017-211836. [Epub ahead of print]

By clicking Accept, you agree to become a member of the UBM Medica Community.